Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulated Protein Degradation02:58

Regulated Protein Degradation

2.5K
2.5K
The Proteasome02:18

The Proteasome

8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study on the Effect and Mechanism of the Outer Membrane Vesicles of <i>Porphyromonas gingivalis</i> on the Function and Extracellular Matrix of Mouse Aortic Smooth Muscle Cells.

Microorganisms·2026
Same author

Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation.

ACS infectious diseases·2026
Same author

Prognostic significance of PCR-based measurable residual disease post-induction and during consolidation in pediatric KMT2A-rearranged acute myeloid leukemia.

Leukemia research·2026
Same author

Quality and reliability of vascular cognitive impairment-related information on Chinese social media platforms.

Medicine·2026
Same author

Diosgenin alleviates hepatic fibrosis via PI3K/Akt/mTOR mediated fatty acid metabolic reprogramming and NF-κB activation.

Journal of ethnopharmacology·2026
Same author

Alternative mRNA splicing events and regulators in epidermal differentiation.

Cell reports·2026

Related Experiment Video

Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K

Recent advances in developing targeted protein degraders.

Binbin Cheng1, Hongqiao Li2, Xiaopeng Peng3

  • 1Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University, Huangshi, 435003, China; Central Laboratory, Wenzhou Medical University Lishui Hospital, Lishui People's Hospital, Lishui, Zhejiang, 323000, China.

European Journal of Medicinal Chemistry
|December 30, 2024
PubMed
Summary

Targeted protein degradation (TPD) uses small molecules to eliminate disease-causing proteins. This review explores TPD ligands, their mechanisms like proteasome or lysosome targeting, and future potential.

Keywords:
HyTTDLYTACsMolecular gluesPROTACsSmall molecule ligandsTargeted protein degradation

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

Related Experiment Videos

Last Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

Area of Science:

  • Biochemistry and Medicinal Chemistry
  • Drug Discovery and Development
  • Molecular Biology

Background:

  • Targeted protein degradation (TPD) is an emerging therapeutic strategy utilizing innovative modalities.
  • Key TPD strategies include proteolysis targeting chimeras (PROTACs), molecular glues, hydrophobic tag tethering degraders (HyTTD), and lysosome-targeted chimeras (LYTACs).
  • Small molecule ligands are crucial components that direct target proteins for degradation.

Purpose of the Study:

  • To provide a comprehensive overview of small molecule ligands employed in TPD.
  • To discuss the design principles, advantages, and limitations of various TPD ligands.
  • To explore the future prospects and developmental trajectory of TPD technology.

Main Methods:

  • Literature review and synthesis of current research on TPD small molecule ligands.
  • Analysis of degradation pathways mediated by proteasome, lysosome, autophagy, and hydrophobic tagging systems.
  • Discussion of design strategies and comparative assessment of TPD approaches.

Main Results:

  • Small molecule ligands are central to TPD, enabling targeted protein elimination.
  • Ligands can harness cellular machinery like the proteasome and lysosome for degradation.
  • Different TPD strategies (PROTACs, molecular glues, etc.) offer unique advantages and face specific challenges.

Conclusions:

  • Small molecule ligands are versatile tools driving the advancement of TPD therapeutics.
  • Understanding ligand design and degradation pathways is key to optimizing TPD efficacy.
  • TPD technology holds significant promise for future drug development and treatment strategies.